Trial Profile

A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects With Carcinoid Syndrome

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Nov 2024 According to a Crinetics Pharmaceuticals media release, data from the Phase 2 clinical study of paltusotine, will be presented at the upcoming North American Neuroendocrine Tumor Society Multidisciplinary NET Medical Symposium (NANETS 2024), taking place November 21-23, 2024, in Chicago.
12 Mar 2024 According to a Crinetics Pharmaceuticals media release, results from Phase 2 study of paltusotine in carcinoid syndrome confirm our decision to move expeditiously toward Phase 3.
12 Mar 2024 According to a Crinetics Pharmaceuticals media release, company will hold a conference call and live webcast on Tuesday, March 12 at 4:30 p.m. Eastern Time to discuss the results from the Phase 2 study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com